#### Medtronic News

Medtronic Reports Third Quarter Net Earnings up 23%; Earnings Per Share Increased 22%; Implantable Cardioverter Defibrillators and Spinal Products Highlight Third Quarter Growth

MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2006--Medtronic, Inc. (NYSE:MDT):

- Company-wide Revenue Increased 9% (Constant Currency Growth of 12%)
- -- Implantable Cardioverter Defibrillator (ICD) Revenue Grew 21% (Constant Currency Growth of 23%)
- -- Spinal Revenue Grew 19% (Constant Currency Growth of 20%)
- -- R&D Spending Increased 16% to \$280 Million

Medtronic, Inc. (NYSE:MDT) today announced record revenue for the quarter ended January 27, 2006, of \$2.770 billion, a 9 percent increase over the \$2.531 billion recorded in the third quarter of fiscal year 2005. On a constant currency basis, growth was 12 percent with a negative currency translation impact of \$72 million or 3 percent.

As reported, third quarter net earnings were \$670 million or \$0.55 per diluted share, an increase of 23 percent and 22 percent respectively over the prior year third quarter. Excluding the litigation charge included in the prior year third quarter, net earnings and earnings per share increased 20 percent.

"Solid overall growth was again led by our two largest product lines, implantable defibrillators and spinal products. These two product lines accounted for about 45 percent of the corporation's revenue and, on a constant currency basis, they collectively grew 22 percent compared to the prior year third quarter," said Art Collins, chairman and chief executive officer of Medtronic. "This year's growth reflects the impact of ongoing investments; for example, during this quarter R&D expenditures increased 16 percent to \$280 million."

### Cardiac Rhythm Management Business

Cardiac Rhythm Management (CRM) quarterly revenue was \$1.263 billion, representing growth of 10 percent over the same period last fiscal year (constant currency growth of 13 percent). ICD revenue was \$723 million in the quarter, representing an increase of 21 percent (constant currency growth of 23 percent). ICD revenue gains underscore the strength of Medtronic's product line and sales and technical support teams. Worldwide pacing revenue was \$426 million in the quarter, a decrease of 1 percent (constant currency growth of 3 percent). Negatively impacted by previously disclosed vendor supply issues, Emergency Response Systems reported revenue of \$99 million, a decrease of 4 percent (constant currency decrease of 1 percent).

### CRM highlights include:

- -- Medtronic's InSync Sentry(TM) CRT-D system, with OptiVol(TM) fluid status monitoring, continued to be well received by physicians and now represents the majority of Medtronic CRT-D units sold worldwide. These products, combined with the EnTrust and Intrinsic ICD families, have strengthened Medtronic's market leadership position.
- -- The EnRhythm pacemaker with Medtronic's unique managed ventricular pacing (MVP) feature helped drive 8 percent pacing growth in the U.S., the strongest performance in over three years.
- The Medtronic CareLink(R) Network continued to expand, with close to 60,000 patients now being monitored by about 750 clinics.

Spinal, ENT and Navigation Businesses

Spinal / Ear, Nose and Throat (ENT) / Navigation revenue for the quarter was \$628 million, representing 17 percent growth over the same period last fiscal year (constant currency growth of 19 percent). Maintaining a track record of strong growth and market share improvement, Spinal revenue of \$534 million increased 19 percent (constant currency growth of 20 percent).

### Spinal highlights include:

- Spinal Biologics revenue increased more than 35 percent as surgeon demand for INFUSE(TM) bone graft increased in both spinal and trauma indications.
- -- Enrollment was completed in the PRESTIGE(R) LP cervical disc clinical trial, Medtronic's third major artificial cervical disc trial for the treatment of degenerative spine disease. Medtronic's portfolio of dynamic stabilization products, which includes the DIAM(TM) System, the MAVERICK(TM) and O-MAV(TM) artificial lumbar discs and the PRESTIGE LP and BRYAN(R) cervical discs, continued to gain momentum and collectively hold the number one market position in Europe.
- Five spinal products received 510(k) clearance from the U.S.
   Food and Drug Administration (FDA), including a new indication for cranial stabilization in cervical spinal fusion for the VERTEX reconstruction system, the world's leading posterior cervical stabilization system.

Neurological and Diabetes Businesses

Neurological and Diabetes quarterly revenue of \$489 million increased 6 percent over the same quarter one year ago (constant currency growth of 9 percent). Neurological revenue of \$307 million and Diabetes revenue of \$182 million both grew 6 percent (constant currency growth of 9 percent).

Neurological and Diabetes highlights include:

- -- Medtronic's RESTORE(TM) rechargeable neurostimulation system with its unique flexible extender that allows for easier device replacement continued to be well received by physicians. RESTORE is estimated to hold the leading market share position in the rapidly growing rechargeable segment of the market and now accounts for the majority of Medtronic Neurostimulation systems sold.
- The U.S. clinical trial for the Intercept(TM) epilepsy control system met an early milestone and enrollment in the trial will accelerate.
- -- Distribution of the Guardian(TM) RT continuous glucose monitoring system was expanded to cover many international markets and select U.S. cities. The system displays glucose readings every five minutes and alerts the patient when glucose levels become too high or low. Diabetes patients will now be able to intervene earlier to maintain healthy glucose control.

Vascular Business

Vascular revenue of \$236 million for the quarter represented 6 percent growth over the same period last fiscal year (constant currency growth of 13 percent).

Vascular highlights included:

- The Endeavor(TM) drug eluting coronary stent continued to be well received by physicians and is now commercially released in over 85 countries outside the U.S. Revenues of \$43 million represented mid- to high-teens market share in countries where the product has been fully commercialized.
- -- The initial clinical trial of Endeavor CR, Medtronic's next-generation drug-eluting stent commenced. Endeavor CR is designed to promote an appropriate healing response for patients with diabetes or complex lesions.

-- The first pre-market approval (PMA) module for the Talent(TM) thoracic stent graft system was submitted to the FDA. Medtronic holds a global market leadership position with the AneuRx(R) and Talent(TM) stent grafts that treat abdominal and thoracic aortic aneurysms (AAA/TAA).

Cardiac Surgery Business

Cardiac Surgery revenue of \$154 million in the quarter declined 6 percent over the same period last fiscal year (constant currency decline of 3 percent). Looking ahead, the company expects to release two new valve repair products in early fiscal year 2007, which should help improve growth in this segment.

**Concluding Comments** 

In reviewing the quarter, Collins concluded, "Medtronic's overall competitive position remains strong as we compete in some of the most attractive segments of the medical technology industry."

Webcast Information

Medtronic will host a webcast today, February 21 at 4:30 pm EST (3:30 CST), to provide information about its businesses for the public, analyst and news media. This quarterly webcast can be accessed by clicking on the Investor Relations link on the Medtronic home page at www.medtronic.com., and this earnings release will be archived at www.medtronic.com/newsroom. Within 24 hours, a replay of the webcast and a transcript of the company's prepared remarks will be available in the "Presentations & Transcripts" section of the Investor Relations homepage.

About Medtronic

Medtronic, Inc., headquartered in Minneapolis, is the world's leading medical technology company, alleviating pain, restoring health and extending life for people with chronic disease. Its Internet address is www.medtronic.com.

This press release contains forward-looking statements, including statements regarding clinical trials, which are subject to risks and uncertainties, such as competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, general economic conditions and others described in Medtronic's Quarterly Report on Form 10-Q for the quarter ended October 28, 2005. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statement.

MEDTRONIC, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(Unaudited)
(in millions, except per share data)

Three months ended Nine months ended -----Jan. 27, Jan. 28, Jan. 27, Jan. 28, 2006 2005 2006 2005

Net sales \$2,769.5 \$2,530.7 \$8,225.3 \$7,276.6

Costs and expenses:

Cost of products sold 698.7 605.6 2,047.3 1,740.7

Research and development

expense 280.3 241.0 818.9 703.4

Selling, general, and

administrative expense 899.7 814.2 2,685.3 2,355.9

Special charges - - 100.0 - Certain litigation - 24.3 - 24.3

Purchased in-process research and development

(IPR&D) - 363.8

Other expense, net 9.6 94.6 101.1 212.1 Interest income (23.7) (13.0) (52.5) (24.4)

Total costs and expenses 1,864.6 1,766.7 6,063.9 5,012.0

------

Earnings before income taxes 904.9 764.0 2,161.4 2,264.6

Provision for income taxes 235.3 219.9 354.7 655.1

-----

Net earnings \$669.6 \$544.1 \$1,806.7 \$1,609.5

-----

Earnings per share:

Basic \$0.55 \$0.45 \$1.49 \$1.33

Diluted \$0.55 \$0.45 \$1.48 \$1.32

Weighted average shares

outstanding:

Basic 1,208.5 1,208.2 1,209.4 1,208.9 Diluted 1,222.8 1,219.1 1,222.6 1,220.0

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP NET EARNINGS
TO CONSOLIDATED ADJUSTED NET EARNINGS

(Unaudited)

(in millions, except per share data)

Three months ended Three months ended January 27, 2006 January 28, 2005

-----

Net earnings, as reported \$669.6 \$544.1 Certain litigation - 15.6 (a)

-----

Adjusted net earnings \$669.6 \$559.7

MEDTRONIC, INC.
RECONCILIATION OF CONSOLIDATED GAAP DILUTED EPS
TO CONSOLIDATED ADJUSTED DILUTED EPS
(Unaudited)

Three months ended Three months ended January 27, 2006 January 28, 2005

-----

Diluted EPS, as reported \$0.55 \$0.45 Certain litigation - 0.01 (a)

Adjusted diluted EPS \$0.55 \$0.46

(a) The \$15.6 million (\$0.01 per share) after-tax certain litigation charge (\$24.3 million pre-tax) is related to the DePuy/AcroMed, Inc. (DePuy/AcroMed) litigation. In addition to disclosing certain litigation charges that are determined in accordance with U.S. generally accepted accounting principles (GAAP), Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this litigation charge. Management believes that this non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates this litigation charge when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition

to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. This non-GAAP financial measure may not be the same as similar measures presented by other companies.

# MEDTRONIC, INC. RECONCILIATION OF CONSOLIDATED GAAP NET EARNINGS TO CONSOLIDATED ADJUSTED NET EARNINGS (Unaudited)

(in millions, except per share data)

-----

 Net earnings, as reported
 \$1,806.7
 \$1,609.5

 Special charges
 65.6 (a)

 Certain litigation
 15.6 (d)

 IPR&D charges
 295.3 (b)

 Income tax adjustments
 (225.0)(c)

Adjusted net earnings \$1,942.6 \$1,625.1

# MEDTRONIC, INC. RECONCILIATION OF CONSOLIDATED GAAP DILUTED EPS TO CONSOLIDATED ADJUSTED DILUTED EPS (Unaudited)

Nine months ended January 27, 2006 Nine months ended January 28, 2005

-----

Adjusted diluted EPS	\$1.59	\$1.33
Income tax adjustments	(0.18)(	-
IPR&D charges	0.24 (b)	-
Certain litigation	-	0.01 (d)
Special charges	0.05 (a)	-
Diluted EPS, as reported	\$1.48	\$1.32

- (a) The \$65.6 million (\$0.05 per share) special charge represents an after-tax charitable donation (\$100.0 million pre-tax) made to The Medtronic Foundation. In addition to disclosing special charges that are determined in accordance with GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this donation. The Company has not made a similar contribution to The Medtronic Foundation since fiscal year 2002. Management believes that this non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates this donation when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. This non-GAAP financial measure may not be the same as similar measures presented by other companies.
- (b) The \$295.3 million (\$0.24 per share) after-tax IPR&D charge (\$363.8 million pre-tax) represents the cumulative impact of pre-tax charges of \$168.7 million related to a technology acquired through the purchase of Transneuronix, Inc. that had not yet reached technological feasability and had no future alternative use, \$175.1 million related to the purchase of spinal technology based devices owned by Gary K. Michelson, M.D. and Karlin Technology, Inc. that had not yet reached technological feasability and had no future alternative use, and \$20.0 million related to a cross-licensing agreement with NeuroPace, Inc. for patent and patent applications on products that had not yet reached technological feasability and had no future alternative use, collectively the IPR&D charges. In addition to disclosing IPR&D that is determined in accordance with GAAP, Medtronic managment believes that in order to properly understand its short-term and long-term

financial trends, investors may find it useful to consider the impact of excluding these IPR&D charges. These IPR&D charges resulted from facts and circumstances that vary in frequency and/or impact on continuing operations. Management believes that this non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates these IPR&D charges when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. This non-GAAP financial measure may not be the same as similar measures presented by other companies.

- (c) The \$225.0 million (\$0.18 per share) tax adjustment represents a \$225.0 million tax benefit associated with the reversal of reserves resulting from favorable agreements reached with the U.S. Internal Revenue Service (IRS) involving the review of fiscal years 1997 through 2002 domestic income tax returns. In addition to disclosing the provision for income taxes that is determined in accordance with GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this tax adjustment. Management believes that this non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations, specifically the effective tax rate. Medtronic management eliminates this tax adjustment when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. This non-GAAP financial measure may not be the same as similar measures presented by other companies.
- (d) The \$15.6 million (\$0.01 per share) after-tax certain litigation charge (\$24.3 million pre-tax) is related to the DePuy/AcroMed litigation. In addition to disclosing certain litigation charges that are determined in accordance with GAAP, Medtronic management believes that in order to properly understand its short-term and long-term financial trends, investors may find it useful to consider the impact of excluding this litigation charge. Management believes that this non-GAAP financial measure provides useful information to investors regarding the underlying business trends and performance of the Company's ongoing operations and is useful for period over period comparisons of such operations. Medtronic management eliminates this litigation charge when evaluating the operating performance of the Company. Investors should consider this non-GAAP measure in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. This non-GAAP financial measure may not be the same as similar measures presented by other companies.

## MEDTRONIC, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Nine months ended

January 27, January 28,

15.4

2006 2005

(dollars in millions)

### **OPERATING ACTIVITIES:**

Net earnings \$1,806.7 \$1,609.5

Adjustments to reconcile net earnings to

net cash provided by operating activities:

Depreciation and amortization 407.1 339.3

Purchased in-process research and

development 363.8

Certain litigation - 24.3
Provision for doubtful accounts 8.2 20.2

Tax benefit from exercise of stock

options 77.0 52.0 Deferred income taxes 182.5

Change in operating assets and

liabilities:

Accounts receivable (123.1) (156.0) (274.2) (80.1) Inventories Accounts payable and accrued (1,047.6)liabilities Other operating assets and liabilities 102.8 (41.2)Net cash provided by operating activities 1,503.2 2,024.0 **INVESTING ACTIVITIES:** Acquisitions, net of cash acquired (285.2)(96.4)Purchase of intellectual property (830.7)Additions to property, plant and equipment (305.4) (306.7) Purchases of marketable securities (4,863.3) (996.8) Sales and maturities of marketable securities 2,849.6 532.8 Other investing activities, net 1.3 76.3 Net cash used in investing activities (3,433.7) (790.8) FINANCING ACTIVITIES: 574.2 Increase in short-term borrowings, net 21.9 Increase in long-term debt, net 993.9 Dividends to shareholders (348.9) (303.6) 444.8 236.7 Issuance of common stock Repurchase of common stock (709.4) (511.0) Net cash provided by (used in) financing activities (556.0)Effect of exchange rate changes on cash and cash equivalents 111.5 (85.4)Net change in cash and cash equivalents (864.4)591.8 Cash and cash equivalents at beginning of period 2,232.2 1,593.7 Cash and cash equivalents at end of period \$1,367.8 \$2,185.5 Supplemental Cash Flow Information Cash Paid For: Income taxes \$580.1 \$365.1 Interest 59.8 34.1 Supplemental Noncash Investing and Financing Activities: Deferred payments for purchases of intellectual property \$30.0 Reclassification of debentures from short-1,973.2 term to long-term debt Reclassification of debentures from long-1,971.4 term to short-term debt MEDTRONIC, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) January 27, April 29, 2006 2005 (dollars in millions, except per share data) **ASSETS** Current assets:

Cash and cash equivalents

\$1,367.8 \$2,232.2

Short-term investments 3,559.0 1,159.4 Accounts receivable, less allowances of \$180.2 and \$174.9, respectively 2,364.6 2,292.7 1,177.2 981.4 s. net 83.2 385 Inventories 83.2 385.6 Deferred tax assets, net Prepaid expenses and other current assets 373.7 370.2 -----Total current assets 8,925.5 7,421.5 Property, plant and equipment 3,709.7 3,628.6 Accumulated depreciation (1,833.8) (1,769.3) Net property, plant and equipment 1,875.9 1,859.3 Goodwill 4,345.0 4,281.2 Other intangible assets, net 1,631.6 1,018.0 1,122.2 1,565.7 Long-term investments Other assets 438.8 471.7 Total assets \$18,339.0 \$16,617.4 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term borrowings \$3,023.2 \$478.6 310.9 371.8 Accounts payable Accrued compensation 612.6 542.2 428.5 923.3 Accrued income taxes Other accrued expenses 496.3 1,064.1 4,871.5 3,380.0 Total current liabilities 1,002.5 1,973.2 Long-term debt Deferred tax liabilities, net 362.8 478.1 176.8 157.9 Long-term accrued compensation Other long-term liabilities 187.8 178.7 Total liabilities 6,601.4 6,167.9 Commitments and contingencies Shareholders' equity: Preferred stock-- par value \$1.00 -- --120.9 121.0 Common stock-- par value \$0.10 11,448.8 10,178.5 Retained earnings Accumulated other non-owner changes in 167.9 150.0 equity Total shareholders' equity 11,737.6 10,449.5 Total liabilities and shareholders' equity \$18,339.0 \$16,617.4 MEDTRONIC, INC. REVENUE BY OPERATING SEGMENT (Unaudited) (\$ millions)

FY 05 FY 05 FY 05 FY 05

QTR 1 QTR 2 QTR 3 QTR 4 TOTAL

```
REPORTED REVENUE:
CARDIAC RHYTHM
MANAGEMENT
                    $1,097 $1,104 $1,150 $1,265 $4,616
   Low Power Pacing
                     451
                         438
                               431
                                      436 1,756
   High Power
                      546
                           598
   Defibrillation
                 551
                                 684 2.379
   Emergency Response
                            104
   Systems
                 79
                      104
                                  126
                                        413
   Other
                 16
                      16
                           17
                                19
                                      68
SPINAL, ENT & NAVIGATION $484 $506 $536 $599 $2,125
  Spinal Constructs
                   317
                        332 343 380 1,372
  Spinal Biologics
                   89
                        99
                            107
                                  118
                                        413
  Ear, Nose & Throat
  (ENT)
                 58
                      55
                           61
                                 67
                                     241
  Navigation
                  20
                       20
                            25
                                  34
                                       99
NEUROLOGICAL and
                  $408 $430 $460 $496 $1,794
 DIABETES
                  170 179
                             184
                                  206
  Neurological
  Gastroenterology &
  Urology
                 42
                      45
                            49
                                 52
                                      188
  Neurologic
                   50
                        53
                                   59
                                        218
  Technologies
                              56
  Diabetes
                 146
                      153
                            171
                                  179
                                        649
VASCULAR
                   $196
                         $201
                               $221 $233
                                            $851
  Stents
                     78
                           86
                                82
                                     317
  Other Coronary
                         71
                              77
                                    89
  Endovascular/
  Peripheral
                       52
                            58
                                 62
                                      226
                       $161 $159 $164 $185 $669
CARDIAC SURGERY
  Valves
                 56
                           56
                                 64
                                     230
                      54
                      79
  Perfusion
                 79
                            80
                                 89
                                      327
  Cardiac Surgery
  Technologies
                   26
                        26
                              28
                                   32
                                        112
  TOTAL
                $2,346 $2,400 $2,531 $2,778 $10,055
ADJUSTMENTS:
 CURRENCY (1)
                     35
                          40
                                59
                                     32
                                         $166
COMPARABLE OPERATIONS (1) $2,311 $2,360 $2,472 $2,746 $9,889
            _____
            FY 06 FY 06 FY 06 FY 06
            QTR 1 QTR 2 QTR 3 QTR 4 TOTAL
REPORTED REVENUE:
CARDIAC RHYTHM
MANAGEMENT
                    $1,268 $1,289 $1,263
                                          $- $3,820
   Low Power Pacing
                     446
                         459
                               426
                                       - 1,331
   High Power
   Defibrillation
                 718
                      733
                            723
                                   - 2,173
   Emergency Response
   Systems
                 87
                       81
                            99
                                     268
   Other
                 17
                      16
                           15
                                     48
SPINAL, ENT & NAVIGATION $589
                              $603 $628
                                             $- $1,820
                         382
                              387
  Spinal Constructs
                   376
                                     - 1,146
  Spinal Biologics
                   128
                        134
                              147
                                        408
  Ear, Nose & Throat
  (ENT)
                      64
                           65
                 65
                                     194
  Navigation
                  20
                      23
                           29
                                      72
NEUROLOGICAL and
 DIABETES
                  $463 $487 $489
                                      $- $1.439
  Neurological
                  186
                       204
                            202
                                        592
  Gastroenterology &
  Urology
                 49
                      48
                            45
                                     141
  Neurologic
```

 Technologies
 55
 57
 60
 172

 Diabetes
 173
 178
 182
 534

VASCULAR \$205 \$225 \$236 \$- \$665

 Stents
 65
 90
 96
 251

 Other Coronary
 81
 78
 83
 242

Endovascular/

Peripheral 59 57 57 - 172

CARDIAC SURGERY \$165 \$161 \$154 \$- \$481

 Valves
 58
 56
 52
 166

 Perfusion
 79
 78
 75
 233

Cardiac Surgery

Technologies 28 27 27 - 82

TOTAL \$2,690 \$2,765 \$2,770 \$- \$8,225

\_\_\_\_\_

#### ADJUSTMENTS:

CURRENCY (1) 26 (3) (72) \$(49)

COMPARABLE OPERATIONS (1) \$2,664 \$2,768 \$2,842 \$- \$8,274

-----

(1) - Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenues.

CONTACT: Medtronic, Inc., Minneapolis Medtronic Investor Relations: Rachael Scherer, 763-505-2694 or Medtronic Public Relations: Rob Clark, 763-505-2635 or Medtronic International:

Yvan Deurbroeck, +41 21 802 7574

SOURCE: Medtronic, Inc.

https://news.medtronic.com/2006-02-21-Medtronic-Reports-Third-Quarter-Net-Earnings-up-23-Earnings-Per-Share-Increased-22-Implantable-Cardioverter-Defibrillators-and-Spinal-Products-Highlight-Third-Quarter-Growth